Cargando…
In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir
Remdesivir (RDV, Veklury®) is an FDA-approved prodrug for the treatment of hospitalized patients with COVID-19. Recent in vitro studies have indicated that human carboxylesterase 1 (CES1) is the major metabolic enzyme catalyzing RDV activation. COVID-19 treatment for hospitalized patients typically...
Autores principales: | Zhang, Qingchen, Melchert, Philip W., Markowitz, John S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367181/ https://www.ncbi.nlm.nih.gov/pubmed/35964681 http://dx.doi.org/10.1016/j.cbi.2022.110097 |
Ejemplares similares
-
The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance
por: Yan, Daisy, et al.
Publicado: (2021) -
Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs
por: Schooley, Robert T., et al.
Publicado: (2021) -
Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs
por: Schooley, Robert T., et al.
Publicado: (2021) -
Metabolic Efficacy of Phosphate Prodrugs and the Remdesivir
Paradigm
por: Wiemer, Andrew J.
Publicado: (2020) -
Nudix hydrolase 18 catalyzes the hydrolysis of active triphosphate metabolites of the antivirals remdesivir, ribavirin, and molnupiravir
por: Jemth, Ann-Sofie, et al.
Publicado: (2022)